Giuseppe Ciaramella is the Chief Scientific Officer of Valera LLC, a fully owned venture of Moderna that focuses on the discovery of vaccines and therapeutics for Infectious Diseases using Moderna’s mRNA technology. He joined Moderna in January 2014 as VP of Immunology and Biotherapeutics and was appointed CSO of the newly formed Valera company in October 2014. He has more than 20 years of drug discovery experience at Moderna, Astrazeneca, Boehringer Ingelheim (BI), Pfizer and Merck, and has held several leadership roles, with a particular focus in the fields of antivirals, immunology and biotherapeutics. Prior to joining Moderna, Giuseppe lead the small molecule Antiviral Strategy at AZ. At BI, he was VP and Head of Collaborative Research where he had responsibility for external R&D and was a member of the WW Research Leadership Team. Prior to BI, Pino spent 14 years at Pfizer in the UK where he held several Discovery leadership positions, including Head of Biotherapeutics, Head of Antiviral and Head of Lead Discovery. During his career, Giuseppe has contributed to several clinical candidates, both small molecule and biologics, and to the anti-HIV drug Maraviroc (SelzentryTM), which won the USA Prix Galien for Best Pharmaceutical in 2008.
Giuseppe holds a PhD in Biochemistry and Molecular Biology from University College London. He is a Fellow of the Royal Society of Chemistry (UK) and he is a member of the Infectious Diseases Society of America (IDSA).